Multifaceted in vivo models for critical psoriasis studies.
Psoriasis causes red, crusty, flaky, crusty patches of skin that are usually covered with silvery scales. It affects roughly 2-3% of the worldwide population, equally among men and women. To this day, it has no known cure, but only a range of treatments that alleviate its symptoms. Psoriasis is a multifactorial condition, with one of its contributing factors being autoimmune diseases (Celiac disease, Crohn’s disease, rheumatoid arthritis); Some experts even believe that Psoriasis is an autoimmune disease itself.
With T-cells carrying out a ruthless onslaught on skin cells in psoriasis, the search for better drugs to treat the condition has to be equally ruthless, and unrelenting. This is exactly what we can promise you at PharmaLegacy. An Unrelenting team of scientists with 15 years of experience in pharmacology. State-of-the-art IL-23 induced hyperplasia in mice and Imiquimod-induced psoriasis in mice and rats models.
Put your trust in the right CRO. Put your trust in PharmaLegacy.
MODELS / SERVICES
Comparison of rmIL-23 and rhIL-23 effect in induced ear epidermal hyperplasia in mice
Case Study: Psoriasis Model in Rats (Imiquimod-Induced)
The capability to succeed:
- AAALAC accredited vivarium
- PK/PD, molecular pharmacology and preliminary toxicology adjacency studies
- FDA part 11 compliant
- Research data electronically managed by BioBook (IDBS, UK)
See why over half of the top 20 pharmaceutical companies trust PharmaLegacy to run their in vivo preclinical studies.
Improving Quality of Life for 3% of the World’s Population
Atopic Dermatitis has become far more commonplace in industrialized nations in recent decades, with studies estimating a 2-3 fold increase in incidence since the 1970s. With relatively safe treatments such as antihistamines providing low efficacy, and more efficacious treatments such as corticosteroids and immunosuppressants carrying the risk of significant side effects, new treatments are needed. Download our Atopic Dermatitis brochure and see sample data and other information on a selection of models PharmaLegacy offers for assessing potential new treatments.